for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celyad SA

CYAD.BR

Latest Trade

8.14EUR

Change

-0.24(-2.86%)

Volume

48,585

Today's Range

8.01

 - 

8.52

52 Week Range

7.63

 - 

25.24

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Latest Developments

Celyad Highlights Safety And Clinical Activity Of CYAD-101

Nov 11 (Reuters) - Celyad SA <CYAD.BR>::CELYAD HIGHLIGHTS SAFETY AND CLINICAL ACTIVITY OF CYAD-101, A FIRST-IN-CLASS, NON-GENE EDITED ALLOGENEIC CAR-T THERAPY FOR MCRC, FROM SITC 34TH ANNUAL MEETING.EXPANSION SEGMENT OF TRIAL ANTICIPATED TO BEGIN IN MID-2020.BEST OVERALL RESPONSE IN ALLOSHRINK TRIAL IN REFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS WHO HAD PREVIOUSLY RECEIVED PRIOR OXALIPLATIN-BASED CHEMOTHERAPY.ENROLLMENT COMPLETED IN DOSE-ESCALATION SEGMENT OF ALLOSHRINK TRIAL WITH ADDITIONAL RESULTS EXPECTED IN FIRST HALF 2020.RESULTS FROM ONGOING, DOSE-ESCALATION ALLOSHRINK PHASE 1 TRIAL DEMONSTRATE ABSENCE OF GRAFT-VERSUS-HOST DISEASE.

Celyad: Closing Of 20 Million Dollars Global Offering

Sept 17 (Reuters) - CELYAD SA <CYAD.BR>::ANNOUNCED ON MONDAY CLOSING OF $20 MILLION GLOBAL OFFERING.GLOBAL OFFERING OF 2,000,000 ORDINARY SHARES COMPRISED OF 1,675,000 ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES (ADSS) OFFERED IN U.S., CANADA AND CERTAIN COUNTRIES OUTSIDE OF EUROPE.PRICE PER ADS OF $10.00.GROSS PROCEEDS TO CELYAD FROM THE GLOBAL OFFERING AMOUNTED TO APPROXIMATELY $20.0 MILLION.GRANTED UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL 300,000 ORDINARY SHARES ON SAME TERMS AND CONDITIONS.

Celyad Announces Pricing of $20.0 Million Global Offering

Sept 12 (Reuters) - CELYAD SA <CYAD.BR>::CELYAD ANNOUNCES PRICING OF $20.0 MILLION GLOBAL OFFERING.PRICING OF GLOBAL OFFERING OF 2,000,000 ORDINARY SHARES, COMPRISED OF 1,717,391 ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES (“ADSS”) OFFERED IN UNITED STATES, CANADA AND CERTAIN COUNTRIES OUTSIDE OF EUROPE.GROSS PROCEEDS TO CELYAD FROM THE GLOBAL OFFERING ARE EXPECTED TO BE APPROXIMATELY $20.0 MILLION.THE CLOSING OF THE GLOBAL OFFERING IS EXPECTED TO OCCUR ON SEPTEMBER 16, 2019, AND IS SUBJECT TO CUSTOMARY CLOSING CONDITIONS..PRICE PER ADS OF $10.00 (THE “U.S. OFFERING”), AND 282,609 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF UNITED STATES AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE PER SHARE OF €9.08.IN CONNECTION WITH GLOBAL OFFERING, CELYAD HAS GRANTED UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 300,000 ORDINARY SHARES (WHICH MAY BE IN THE FORM OF ADSS) ON SAME TERMS AND CONDITIONS.

Celyad SA - Intends To Offer & Sell Up To 2 Million Ordinary Shares In A Global Offering

Celyad SA <CYAD.BR>::CELYAD ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING.CELYAD SA - INTENDS TO OFFER & SELL UP TO 2 MILLION ORDINARY SHARES IN A GLOBAL OFFERING.CELYAD - TRADING OF ORDINARY SHARES TO BE SUSPENDED ON EURONEXT BRUSSELS & EURONEXT PARIS PENDING ANNOUNCEMENT OF PRICING OF GLOBAL OFFERING.CELYAD SA - GLOBAL OFFERING COMPRISED OF OFFER OF ORDINARY SHARES IN FORM OF ADSS IN UNITED STATES, CANADA & SOME COUNTRIES OUTSIDE OF EUROPE.CELYAD - GLOBAL OFFERING COMPRISED OF OFFER OF ORDINARY SHARES IN EUROPE & SOME COUNTRIES OUTSIDE THE U.S., CANADA IN CONCURRENT PRIVATE PLACEMENT.

Celyad: Updates on CYAD-01 Produced with OptimAb Manufacturing Process

Sept 4 (Reuters) - CELYAD SA <CYAD.BR>::CELYAD SUCCESSFULLY DOSES FIRST PATIENT WITH CYAD-01 PRODUCED WITH OPTIMAB MANUFACTURING PROCESS.TODAY ANNOUNCED SUCCESSFUL ADMINISTRATION OF CYAD-01 PRODUCED WITH OPTIMAB MANUFACTURING PROCESS TO A PATIENT ENROLLED IN COHORT 3 (300 MILLION CELLS) OF PHASE 1 DEPLETHINK TRIAL.OPTIMAB MANUFACTURING PROCESS HAS SHOWN EXCITING ACTIVITY IN PRECLINICAL MODELS - COO.WE LOOK FORWARD TO REPORTING PRELIMINARY DATA FROM PATIENTS ENROLLED IN DEPLETHINK TRIAL TREATED WITH CYAD-01 PRODUCED WITH OPTIMAB PROCESS BY END OF YEAR.

Celyad Reports Half Year 2019 Financial Results And Second Quarter Business Highlights

Aug 22 (Reuters) - Celyad SA <CYAD.BR>::CELYAD REPORTS HALF YEAR 2019 FINANCIAL RESULTS AND SECOND QUARTER BUSINESS HIGHLIGHTS.

Celyad H1 Operating Loss Narrows To EUR 15.9 Mln

Aug 23 (Reuters) - CELYAD SA <CYAD.BR>::ANNOUNCED ON THURSDAY H1 OPERATING LOSS EUR 15.9 MLN VS LOSS EUR 18.8 MLN YR AGO.H1 NET CASH USED IN OPERATIONS LOSS EUR 16.1 MLN VS LOSS EUR 13.9 MLN YR AGO.H1 TREASURY POSITION EUR 33.7 MLN VS EUR 62.4 MLN YR AGO.THE CO'S LICENSE AND COLLABORATION AGREEMENTS HAVE GENERATED NO REVENUE IN FIRST HALF OF 2019.WE APPROACH SEVERAL CLINICAL MILESTONES EXPECTED OVER THE NEXT SEVERAL MONTHS - CEO.

Celyad Announces Strategic Updates To The Autologous R/R Aml And Mds Program

July 1 (Reuters) - Celyad SA <CYAD.BR>::CELYAD ANNOUNCES STRATEGIC UPDATES TO THE AUTOLOGOUS R/R AML AND MDS PROGRAM.CELYAD SA - FDA ACCEPTED INVESTIGATIONAL NEW DRUG APPLICATION TO COMMENCE CLINICAL TRIALS FOR NEXT-GENERATION, CAR-T CANDIDATE, CYAD-02.CELYAD SA - FDA AND FAMHP ACCEPTED PROPOSAL TO UTILIZE NEW, PROPRIETARY 'OPTIMAB' MANUFACTURING PROCESS FOR BOTH CYAD-01 AND CYAD-02.

Celyad Updates On Cyad-01

June 17 (Reuters) - Celyad SA <CYAD.BR>::CELYAD PRESENTS CLINICAL UPDATE FOR CYAD-01 AT 24TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION.PRELIMINARY DATA FROM COHORT 10 OF THINK TRIAL EVALUATING DENSER SCHEDULE OF INFUSIONS OF CYAD-01 WITHOUT PRECONDITIONING SHOWED BETTER CELL ENGRAFTMENT COMPARED TO BIWEEKLY INJECTIONS OF CYAD-01 WITHOUT PRECONDITIONING.RESULTS FROM ONGOING PHASE 1 THINK AND DEPLETHINK TRIALS EVALUATING CYAD-01 CONTINUE TO SUPPORT THERAPEUTIC CLINICAL DEVELOPMENT OF NKG2D-BASED CAR-T THERAPY PRODUCT CANDIDATE.

Celyad Announces Q1 2019 Financial Results And Recent Business Highlights

May 9 (Reuters) - CELYAD SA <CYAD.BR>::CELYAD ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.CLINICAL UPDATES FROM PHASE 1 THINK AND DEPLETHINK TRIALS ARE ANTICIPATED BY MID-2019.COMPANY ENDED Q1 WITH EUR 40.5 MILLION ($45.4 MILLION) IN CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS.FOR FY 2019 SEES ADVANCEMENT TOWARDS AN IND APPLICATION WITH PRECLINICAL DEVELOPMENT OF NEXT-GENERATION NKG2D-BASED CAR-T, CYAD-02.NET CASH BURN OVER Q1 OF 2019 AMOUNTED TO EUR 8.6 MILLION, IN LINE WITH EXPECTATIONS.CONFIRMS ITS PREVIOUS GUIDANCE THAT ITS TREASURY POSITION SHOULD BE SUFFICIENT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS, BASED ON CURRENT SCOPE OF ACTIVITIES, UNTIL MID-2020.FOR FY 2019 SEES FURTHER PURSUE DEVELOPMENT OF PROPRIETARY NON-GENE EDITED ALLOGENEIC SHRNA PLATFORM AND PROGRESS TOWARDS IND APPLICATIONS FOR CYAD-200 SERIES OF SHRNA-BASED CAR-T CANDIDATES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up